Skip to content

News -

Make the most of serialization

Change is afoot for pharmaceutical companies, with new serialisation legislation on the agenda. To help stem the problem of drug counterfeiting, they will be required to adopt a unique serial number labelling system and adapt their business processes accordingly. Torben Vogt, life sciences expert at NNIT, explains how companies can derive real business value from the investments they are now required to make.

Drug counterfeiting has long been an issue in the life sciences industry, and the problem has grown in severity over the past ten years. Because drugs are commercial brands, there is significant money to be made on the black market from counterfeiting big-name products. This can lead to heavy loss of revenue – a WTO estimate places the figure at $200 billion per annum – and, more seriously, millions of deaths each year. 

"The problem with counterfeit pharmaceuticals has been increasing rapidly," says Torben Vogt, life sciences industry expert at IT consultancy NNIT. "Obviously it’s a serious concern both from the healthcare authorities’ and the regulators’ point of view." 

Luckily, the situation is under scrutiny. Over the coming years, serialisation legislation will come into effect in all major markets – a measure expressly intended to minimise counterfeiting and, most importantly, save lives. All life sciences businesses will be required to place a unique serial number on each pack of drugs, which can be machine-read at the point of sale. Some countries already have active legislation in place, for instance China and Turkey, whereas the US and EU markets will be called for compliance by 2015 and 2017 respectively.

 

Related links

Topics

Contacts

Tina Joanne Hindsbo

Tina Joanne Hindsbo

Press contact Head of Public & Media Relations +45 3077 9578
Sofie Mand Steffens

Sofie Mand Steffens

Press contact Senior Communications Consultant +45 3077 8337

Related content

Global Tracking Regulations Present Challenges and Benefits

Drug makers are facing an ever-increasing challenge as more countries implement serialization and tracking regulations and set compliance deadlines in an effort to ensure the safety and quality of prescription drugs being sold within their borders. Complying with regulations coming into effect will be a demanding task due to a lack of global harmonization.

ISO IDMP is the next after xEVMPD

ISO IDMP is the next wave in the pharmacovigilance legislation after xEVMPD. But with a global scope and requiring data integration from the entire company it is a much bigger wave. ISO IDMP will transform your regulatory IT strategy.

BI tool for smooth submission planning and execution

Regulatory approval for pharmaceutical products can be difficult to obtain, not least because the submission process is often slow and prone to errors. Thomas Svendsen and Peter Noes of NNIT tell World Pharmaceutical Frontiers how regulatory teams can use a business intelligence tool to monitor submission status and hasten time to market.

PSMF establishment and maintenance, business as usual?

Since the implementation of Directive 2010/84 and Regulation 1235/2010, marketing authorisation holders (MAHs) with products on the European market are obliged to maintain, and make available upon request, a Pharmacovigilance System Master File (PSMF).

NNIT SafeCoder

NNIT SafeCoder

To prevent counterfeit, regulation requiring serialization is enforced. But even serial numbers can be counterfeited, especially if batches have sequential codes. Enter the need to generate unique bar codes and serial numbers that are not computed algorithmically. Such capability also needs to operate globally to ensure compliance around the world. NNIT's SafeCoder does exactly this.